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Abstract
Background: Tumstatin is a segment of the collagen-IV protein that is markedly reduced in the airways of asthmatics.
Tumstatin can play an important role in the development of airway remodelling associated with asthma due to its anti-
angiogenic properties. This study assessed the anti-angiogenic properties of smaller peptides derived from tumstatin, which
contain the interface tumstatin uses to interact with the aVb3 integrin.
Methods: Primary human lung endothelial cells were exposed to the LF-15, T3 and T7 tumstatin-derived peptides and
assessed for cell viability and tube formation in vitro. The impact of the anti-angiogenic properties on airways
hyperresponsiveness (AHR) was then examined using a murine model of chronic OVA-induced allergic airways disease.
Results: The LF-15 and T7 peptides significantly reduced endothelial cell viability and attenuated tube formation in vitro.
Mice exposed to OVA+ LF-15 or OVA+T7 also had reduced total lung vascularity and AHR was attenuated compared to mice
exposed to OVA alone. T3 peptides reduced cell viability but had no effect on any other parameters.
Conclusion: The LF-15 and T7 peptides may be appropriate candidates for use as novel pharmacotherapies due to their
small size and anti-angiogenic properties observed in vitro and in vivo.
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Introduction
Asthma is a chronic respiratory disease affecting over 300
million people worldwide. One of the most consistent and striking
findings in asthma is the structural remodelling of the airway walls,
which can contribute to the physiological changes in lung function
observed in asthma [1]. Characteristic changes of airway
remodelling include epithelial dysplasia, increased bulk of the
extracellular matrix and airway smooth muscle layer, and an
increased number of blood vessels in the lamina propria and
adventitia of the airway wall [2]. Since blood vessels play an
important role in the supply of nutrients and oxygen to tissues and
the removal of metabolic waste products, the vascularity of the
airway wall may be a crucial determinant in airway remodelling.
Angiogenesis is also likely to contribute to the chronic
inflammation which occurs in the asthmatic lung. Indeed,
angiogenesis and inflammation are two interrelated processes.
Influx of inflammatory cells into the airway wall and lumen from
the systemic circulation occurs via extravasation across activated
endothelial cells. This in turn can promote hypoxia of the inflamed
tissue, which then provides the stimulus for further angiogenesis.
The greater number of blood vessels provides the potential for
increased production of inflammatory mediators and an increased
surface area of activated endothelium, thus adding to the
inflammatory burden [3].
In humans with asthma the (indirect) relationship between
inflammation and airways hyperresponsiveness (AHR) is complex
and multifactorial, and likely is different in the different endotypes
of asthma. However it has been shown that treatment with only
corticosteroids reduces AHR to provocative stimuli [4]. In animal
models of allergic airways disease, a proxy for asthma, where is it
possible to genetically delete or overexpress a number of
mediators, several inflammatory mediators have been found to
be necessary for the development of AHR. Given the relationship
between angiogenesis, inflammation and AHR, it is reasonable to
hypothesise that reducing blood vessel number would also reduce
inflammation and AHR.
Angiogenesis is a complex biological process controlled by the
balance of pro- and anti-angiogenic factors [5]. We have
previously compared a number of anti-angiogenic factors between
asthmatic and non-asthmatic airways and found that tumstatin,
the NC1 domain of the collagen IV a3 chain, was markedly
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reduced in the airways of people with asthma [5]. Importantly,
increasing tumstatin expression in a murine model of allergic
airways disease (AAD) inhibited angiogenesis, pulmonary inflam-
mation and AHR) [5]. These findings suggest that tumstatin,
delivered directly to the airways, may have therapeutic potential in
asthma. A key step in this development is to identify components
of the native tumstatin molecule which can be easily synthesised.
Several tumstatin-derived anti-angiogenic peptides have been
described, the most potent of which are the overlapping peptides
T3 (69–88 amino acids) and T7 (74–98 amino acids) [6].
Eikesdal et al identified an interactive interface for the T7
peptide on the aVb3 integrin involving the amino acids leucine,
valine and aspartic acid and showed that this region was essential
for T79s anti-angiogenic activity [6]. Interestingly, these amino
acids are found in this overlapping region of the T3 and T7
peptides [6]. Given the prediction that the active anti-angiogenic
site is located in this region, we hypothesised that a novel peptide
consisting only of the overlapping region, which we termed LF-15,
would possess the anti-angiogenic properties of both T3 and T7
and may also have greater efficacy. We also hypothesised that the
LF-15 peptide would retain tumstatin’s ability to inhibit AHR and
pulmonary inflammation. We envisage that LF-15 may be an
attractive therapeutic candidate due to its smaller size, potentially
increasing its bioavailability whilst reducing manufacturing costs
compared to tumstatin [7]. To this end, this study aimed to
investigate LF-159s anti-angiogenic capacity in comparison to T3
and T7 using a range of in-vitro angiogenic assays, and a murine
model of chronic AAD in which we evaluated the ability of LF-15
to inhibit angiogenesis, inflammation and AHR.
Methods
Ethics statement
Human airway tissue was obtained from explanted and resected
lungs and post mortem organ donors with ethical approval from
The University of Sydney and participating hospitals (Concord
Repatriation General Hospital, Sydney South West Area Health
Service and Royal Price Alfred Hospital) for sample collection. All
volunteers, or their next of kin, provided written informed consent.
Ethical approval for experiments on animals was given by the
Animal Care and Ethics Committee of the University of New-
castle.
Endothelial cells
Primary endothelial cells were cultured from explanted lungs, as
previously described [5], and grown in tissue culture flasks pre-
coated with 0.2% (w/v) gelatine (Sigma-Aldrich, St Louis, USA)
which contained Ham’s F-12 culture medium (Invitrogen,
Carlsbad, USA), supplemented with 15 mM HEPES (Sigma-
Aldrich), 0.035 mg/ml Endothelial Cell Growth Supplement
(ECGS) (Sigma-Aldrich), 20 U/ml Heparin (Sigma-Aldrich),
20% FBS (JRH Biosciences, Melbourne, Australia) and antibiotics
(1 U/ml penicillin, 1mg/ml streptomycin and 250 ng/ml ampho-
tericin) (Invitrogen). Cells between passages 3-6 were used for all
experiments. Human Umbilical Vein Endothelial Cells (HuVEC)
were purchased from the American Type Culture Collection, VA
USA (Catalogue No. CRL-1730).
Stimulation with LF-15, T3 and T7 peptides
Custom-made T3 (69–88) and LF-15 (74–88) peptides were
obtained from GL Biochem Ltd, Shanghai, China, and T7
peptides were obtained from Proteomics International Pty Ltd,
Perth, Australia (see figure 1). Endothelial cells were seeded into 96
well plates at a density of 16104 cells/cm2 in HAMS Nutrient F-
12 (JRH Biosciences) containing 20% FBS and 35mg/ml ECGS
(BD Biosciences) and grown for a period of 24 hours at 37uC in
5% CO2. Cells were then quiesced in F12 supplemented with
0.1% BSA for 24 hours. Cells were then treated with 4.5mM LF-
15, T3 or T7 peptides or vehicle control (acetonitrile and TFA) in
growth medium and incubated at 37uC in 5% CO2. Peptides were
replenished after 24, 72 and 144 hours.
MTT assay
The effect of the T3, T7 and LF-15 peptides on cell viability was
assessed using a commercially available 3-(4,5-Dimethylthiazol-2-
yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay (Sigma-Al-
drich). To assess for cytotoxicity using the MTT assay, cells were
grown and treated in 96 well plates as per experimental protocol
before the addition of 10ml sterile MTT (5 mg/ml) per well six
hours before the experiment was due to conclude on Days 3, 7 and
9. After six hours, 100ml of 10% sodium dodecyl sulphate (SDS)
(wt/vol) (Amresco, Solon, USA) in 0.01 M HCL (ThermoFisher
Scientific, VIC, Australia) was added to each well and plates were
left to incubate overnight at 37uC in 5% CO2. Absorbance was
measured at 570 nm with a background reading of 690 nm using
a Wallac-1000 plate reader and software (PerkinElmer, Massa-
chusetts, USA).
Tube formation assay
The BD BioCoat Angiogenesis system - endothelial cell tube
formation - Matrigel assay (BD Biosciences, MA USA) was used to
assess the anti-angiogenic activity of the T3, T7 and LF-15
peptides. Endothelial cells were seeded onto a 96 well plate at
46105 cells/ml in F-12 media with ECGS containing 10% FBS,
with 100 ng/ml angiopoietin-1 (R&D systems, Minneapolis, USA)
300 ng/ml ephrine B2 (R&D systems) and 100 ng/ml VEGF
(R&D systems). The T3, T7 and LF-15 peptides or corresponding
vehicle controls, were added to triplicate wells at a concentration
of 4.5mM. After 18 hours incubation at 37uC in 5% CO2, tube
formation was visualised using an inverted light microscope.
Images were taken using a digital camera (Olympus CAMEDIA C-
4000) and the total number of tubes per well were counted
manually.
Chronic OVA-induced AAD
A murine model of chronic OVA-induced AAD was generated
as previously described [5,8,9]. Balb/C mice were administered
tumstatin peptides diluted in PBS at a concentration of 30 ng or
300 ng per 20 g body weight or PBS alone once a day from days
25 to 115. Specific airway resistance to inhaled methacholine (3, 5,
and 10 mg/ml) was calculated on Day 115 after which the mice
were sacrificed, and the left lungs were removed and inflated with
30% formalin/PBS for 10 minutes [5]. Lungs were then fixed in
4% formaldehyde solution for immunohistological analysis.
Histology
The degree of airway vascularity and extent of inflammation
within the airways was assessed by histology. 5mm sections of lung
specimens were stained with Harris haematoxylin (Sigma-Aldrich),
washed using running tap water, then placed in acid alcohol
(Sigma-Aldrich) to differentiate. Sections were then washed in
running tap water and blued in Scott’s tap water (Sigma-Aldrich).
After rinsing in tap water, sections were stained with eosin (Sigma-
Aldrich) then dehydrated through graded alcohols, cleared in
xylene (MP Biomedicals Inc, Santa Ana, USA) and mounted using
Faramount aqueous mounting medium (DakoCytomation,
Tumstatin Peptides Attenuate AAD
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Glostrup, Denmark) and coverslipped. Sections were graded as per
custom histopathology criteria designed by Horvat et al [10].
Endoglin/CD105 Immunohistochemistry. Immunohisto-
chemistry was used to assess the effect of the peptides T3, T7 and
LF15 on the number of blood vessels present in lung tissue. Briefly,
slides were treated with peroxidase blocking reagent (DakoCytoma-
tion) for 30 mins then washed in x2 changes of dH2O. Slides were
then blocked with blocking serum (VECTASTAIN Elite ABCKIT,
Vector laboratories). Primary antibody (goat anti-mouse CD105,
R&D Systems) or isotype control at a concentration of 15mg/ml was
added to each section and incubated for 30 mins at room temp.
After washing with x2 changes of T-PBS, slides were incubated with
biotinylated secondary antibody (VECTASTAIN Elite ABC KIT,
Vector laboratories). Slides were washed in T-PBS and incubated
with Vectastain elite ABC reagent (VECTASTAIN Elite ABCKIT,
Vector laboratories) for 30 mins. Next, slides were washed in T-PBS
and incubated with DAB (DakoCytomation) for 10 mins. Slides
were washed with dH2O, dehydrated and mounted.
Statistical analysis
All data were analysed using GraphPad PRISM 5.0 (GraphPad,
La Jolla, USA). Statistical analysis was performed using one way
and two way analysis of variance (ANOVA) with appropriate post-
hoc tests depending on Gaussian distribution of data. Differences
were considered significant when p,0.05.
Results
LF-15, T3 and T7 decrease primary lung endothelial cell
viability
Primary lung endothelial cell viability following 3, 7 and 9 days
treatment with the LF-15, T3 and T7 tumstatin-derived peptides
was assessed using the MTT assay. All three peptides significantly
reduced cell viability at all time points (Figure 2; p,0.05 vs
medium alone), with the exception of LF-15 at Day 3. At Days 7
and 9 all peptides had reduced cell viability to a similar extent
(statistical analysis not performed).
LF-15 and T7, but not T3, inhibit endothelial cell tube
formation
The ability of LF-15, T3, and T7 to inhibit primary lung
endothelial cell tube formation was evaluated using an in-vitro
angiogenesis assay (Figure 3A). Treatment of primary lung
endothelial cells with LF-15 or T7 peptides for 18 hours
significantly decreased the number of tubes formed by 18% and
53% respectively (Figure 3B; p,0.05 vs control). In contrast,
treatment of primary lung endothelial cells with the T3 peptide did
not affect tube formation.
Since we observed differential effects of LF-15 and T7 in
comparison to T3, in terms of inhibiting primary pulmonary
endothelial cell tube formation, we repeated the experiments using
HuVECs to investigate if this differential efficacy was restricted to
lung endothelial cells. In this set of experiments, only LF-15
affected tube formation in HuVECs, whereby tube formation was
significantly reduced by 44% (Figure 3C; p,0.05 vs control). T7
and T3 peptides had no effect on HuVec tube formation.
LF-15 and T7, but not T3, suppress AHR in chronic OVA-
induced AAD
A murine model of chronic OVA-induced AAD was used to
examine the anti-angiogenic properties of the peptides in vivo.
BALB/c mice that were chronically exposed to OVA +/2
vehicle demonstrated a significantly greater increase in airway
resistance to methacholine at 5 and 10 mg/ml than saline-treated
mice (Figure 4; p,0.01 vs sham). In the mice treated with OVA+
LF-15 (300 ng/ml) airway resistance was significantly lower than
those treated with only OVA at 5 and 10 mg/ml methacholine
(Figure 4; p,0.05 vs OVA + vehicle control). Similarly, in the
mice treated with OVA+ T7 (300 ng/ml) airway resistance was
significantly lower than those treated with only OVA at 5 and
10 mg/ml methacholine (Figure 4; p,0.05 vs OVA + vehicle
control). In contrast, the T3 peptide had no effect on airway
resistance to methacholine.
LF-15 and T7, but not T3, decrease lung blood vessel area
in chronic OVA-induced AAD
The development of AAD in BALB/c mice treated with OVA
coincided with a significant increase in the total lung area
occupied by blood vessels compared to saline-treated mice which
did not develop AAD (4.2% vs 2.7% respectively) (Figure 5;
p,0.05 vs sham).
OVA-treated mice that were also treated with LF-15 or T7 had
a significantly lower total lung area occupied by blood vessels
(Figure 5; p,0.05 vs OVA). The total lung area of blood vessels in
these mice was similar to those which were not exposed to OVA.
In contrast, mice treated with OVA+T3 had the same total lung
area occupied by blood vessels as mice treated with OVA alone
(Figure 5).
LF-15 and T7 decrease pulmonary inflammation in
chronic OVA-induced AAD
In the murine model of AAD, chronic treatment with OVA
significantly increased pulmonary inflammation as measured by a
scoring system developed to quantify inflammatory cells inflam-
mation in H&E stained sections [10] (Figure 5; p,0.001 vs sham).
When OVA-treated mice were also exposed to LF-15, the extent
of pulmonary inflammation was significantly decreased (Figure 6;
p,0.05 vs OVA). In comparison, treatment with T3 or T7
peptides had no effect on pulmonary inflammation.
Discussion
This study has demonstrated for the first time using a murine
model of chronic OVA-induced AAD that the novel LF-15
Figure 1. Amino acids sequences of the T3 (2.4 kDa), T7 (3 kDa) and LF15 (1.8 kDa) peptides in comparison to tumstatin (28 kDa).
LF15 (amino acids 74–88) encompasses the overlapping region shared by the T3 (69–88) and T7 (74–98) peptides. Peptide integrin binding sites
involve the amino acids L (78, Leucine), V (82, Valine) and D (84, Aspartic acid).
doi:10.1371/journal.pone.0085655.g001
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Figure 2. T3, T7 and LF-15 inhibit mitochondrial function in
primary lung endothelial cells. Cells were treated with T3 or T7 or
LF-15 peptides for 3 (A), 7 (B) and 9 (C) days before mitochondrial
function assessed using the MMT assay. *p,0.05,**p,0.01,***p,0.001
vs medium alone, n = 8.
doi:10.1371/journal.pone.0085655.g002
Figure 3. LF-15 decreased endothelial tube formation. LF-15
decreased endothelial tube by primary lung endothelial cells (B) and
HUVECs (C). Cells were treated with T3 or T7 or LF-15 peptides for
18 hours before the extent of tube formation was assessed by light
microscopy. Image (A) is a representative image of tube formation
following treatment with the LF-15 peptide. *p,0.05,**p,0.01,
***p,0.001 vs medium alone, n = 6.
doi:10.1371/journal.pone.0085655.g003
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peptide, derived from the native tumstatin molecule, can inhibit
endothelial cell viability and tube formation in vitro, and suppress
pulmonary inflammation, angiogenesis and AHR in vivo. There-
fore, LF-15 may have therapeutic potential in asthma. Further-
more, this study also demonstrated that LF-15 appeared to be
more biologically active and was as good, if not superior, to T3
and T7 at attenuating angiogenesis and aspects of AAD. This may
be due to LF-15 encompassing properties of both T3 and T7, as
the LF-15 peptide is comprised of the overlapping area between
the T3 and T7 peptides, which contains the interface that interacts
with integrins [6].
We used a range of contemporary angiogenic in-vitro assays in
addition to evaluating the efficacy of the peptides in an in-vivo
model of AAD. We found that all three peptides reduced
endothelial cell viability at days 7 and 9. However at day 3, LF-
15 did not affect viability, whilst T3 and T7 did. We are not
certain why this might be the case, but potentially LF-15 might
have a slower mechanism of action or reduced potency in this
assay. When we assessed the ability of the peptides to inhibit
endothelial cell tube formation, only LF-15 and T7 inhibited tube
formation. This suggests that the attenuation of tube formation
was not purely a result of reduced cell viability. Furthermore, in
our in-vivo model of AAD, LF-15 and T7 inhibited the
development of AHR, blood vessel formation and pulmonary
inflammation but the T3 peptide did not affect any features of
AAD tested. Therefore it may be reasonable to conclude that the
Figure 4. LF-15 and T7 attenuate OVA-induced airways
resistance in a murine model of allergic airways disease. OVA
sensitised mice were exposed to the T3, T7 and LF-15 between Day 25
and Day 115 before specific airway resistance following methacholine
challenge was assessed. *p,0.05 OVA+LF-15 vs OVA+ Vehicle control,
#p,0.05 OVA+Vehicle control vs Sham control, $p,0.05 OVA+T7 vs
OVA+ Vehicle control, n = 6.
doi:10.1371/journal.pone.0085655.g004
Figure 5. LF-15 and T7 attenuate OVA-induced changes in lung blood vessel area in a murine model of allergic airways disease. OVA
sensitised mice were exposed to the T3, T7 and LF-15 between Day 25 and Day 115 before mice were sacrificed and the blood vessel area in the lungs
was determined by counting CD105 positive blood vessels.*p,0.05 Sham vs OVA, $p,0.05 vs OVA, $$p,0.01 vs OVA, n= 8.
doi:10.1371/journal.pone.0085655.g005
Figure 6. LF-15 attenuates OVA-induced pulmonary inflamma-
tion in a murine model of allergic airways disease. OVA
sensitised mice were exposed to the T3, T7 and LF-15 between Day
25 and Day 115 before mice were sacrificed and the extent of
pulmonary inflammation was determined by H&E staining. ***p,0.05
Sham vs OVA, *p,0.05 LF-15 300 ng vs OVA, n= 8.
doi:10.1371/journal.pone.0085655.g006
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mechanisms by which these peptides inhibited the development of
these features of AAD is more complex than solely a reduction in
endothelial cell viability.
The concentrations of peptides used in-vitro in this study were
based on the effective concentrations used by Maeshima et al.,
2001 [11], and our previous study [5], which showed that the
effective concentrations of T3 and T7 were between 1-4.5 mM. As
the interactive interface is the same for all three peptides [6], it is
unlikely that potency per se accounts for the differences observed
between T3 compared to LF-15 and T7. However, it is worth
noting that the effective concentrations of T3 and T7 were based
upon inhibition of cellular viability [5,11], which was induced by
all three peptides in the current study. Theoretical mapping of the
T7 peptide and the aVb3 integrin predicted binding to occur in
the region which does not overlap with the T3 peptide (i.e. LF-15)
[12]. Thus, it would be expected that T3 and T7 would have
different biological activities, as we have observed. However,
because LF-15 was as active as the T7 peptide, this suggests that
either the region which binds to the aVb3 integrin is in this region,
or the mechanism of action of both LF-15 and T3 is independent
of this particular integrin.
We are not certain why the peptides have different biological
properties in different assays, but speculate that the T3 peptide
contains an inhibitory motif in the region that is not overlapping
with T7 and LF-15. Whilst we have no specific data to support this
argument, there is good evidence that collagen derived fragments
containing as few as three amino acids can have observable
biological activity [13].
A murine model of chronic OVA-induced AAD was used to
examine the biological activities of the peptides. Whilst acute
models of AAD do not demonstrate angiogenesis [11], chronic
models are characterised by the development of persistent
inflammation, AHR and aspects of airway remodelling that
include angiogenesis [3,6]. These characteristics of chronic models
of AAD are consistent with asthma in humans [14,15]. We
previously examined the anti-angiogenic activity of tumstatin in-
vivo using a chronic OVA-induced model of AAD, and found that
the full length protein inhibited angiogenesis, reduced pulmonary
inflammation, and improved AHR [5]. These findings are
furthered by our current study that demonstrated that LF-15
and T7 also produced these changes. Future studies that directly
compare LF-15 and T7 with native tumstatin would be useful in
determining the clinical potential of these molecules and paving
the path for clinical trials.
The smaller size of the LF-15 peptide may be appealing
compared to the full-length tumstatin molecule or the larger T7
peptide for pharmaceutical application. The smaller sized peptide
would make for more cost effective production. However clinical
trials would be needed to verify if these observations are
reproducible in humans. In conclusion, in this study we found
that the novel tumstatin-derived peptide LF-15 is more effective
than the T3 and T7 peptides in suppressing angiogenesis,
pulmonary inflammation and AHR in-vitro and in-vivo, and
therefore may represent a promising therapeutic for the treatment
of asthma.
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